David T. Teachey, MD

David T. Teachey, MD, is an attending physician and researcher at CHOP with expertise in both oncology and hematology.

Areas of Expertise: Autoimmune Diseases: Blood and marrow transplantation
Appointments and Referrals: 1-800-TRY-CHOP

  • Background

    My expertise is in both oncology and hematology. Although the majority of my time is spent in the laboratory, I enjoy taking care of patients at Children's Hospital. My research has given me a broad clinical approach that helps me diagnose and treat the rare child who is "off the grid," particularly when there is an oncology/hematology problem that has gone unsolved. I also specialize in hematopoietic stem cell transplant (bone marrow transplant) and use my expertise in transplant to help treat patients with autoimmune diseases.

    My clinical research is focused on better understanding diseases of white blood cells in children, in particular leukemia and a rare disorder called autoimmune lymphoproliferative syndrome (ALPS). I focus on creating novel therapeutics for leukemia and ALPS, and have been successful in bringing drugs from the bench to the bedside to treat children with these conditions.

    I am the principal investigator for a clinical trial that is using the mTOR inhibitor rapamycin (sirolimus) in children with multiple medical conditions. mTOR is a key protein in a pathway that regulates cell activities including growth and survival. The autoimmune conditions we are looking at in this trial include ALPS, chronic Immune Thrombocytopenic Purpura (ITP, a blood disorder that involves the immune and blood clotting systems) and lupus (a chronic, inflammatory autoimmune disorder.) I also run an ongoing multi-institutional trial to diagnose and better characterize children with ALPS.

    My basic science research focuses on the same two areas: leukemia and autoimmune diseases. My first area of interest is the signal transduction pathways and inhibitors of those pathways in acute lymphoblastic leukemia (ALL). My lab targets the mTOR signaling pathway with novel therapeutics. We use xenograft (tissue grafts from one species to another) models to study the efficacy and action of those therapeutic agents directly on leukemia cells removed from children. This work has led to a number of nationwide Children's Oncology Group-initiated clinical trials that test mTOR inhibitors in patients with ALL.

    The other major area of basic research in my lab centers on investigating novel therapeutics and signaling pathways in autoimmune diseases, particularly ALPS. Using preclinical models, I am targeting both mTOR and Notch cell signaling as treatment approaches for patients with ALPS and other autoimmune diseases. I am also interested in understanding lymphocyte biology in ALPS and other autoimmune diseases.

    I became interested in ALPS as a doctor in training. We had patients with this disorder and couldn't figure out what it was or how to treat it. Now I run the one of the biggest clinics in the world for ALPS. Because of our new treatments, patients are doing better than ever before.

    At Children's Hospital, we are somewhat unique in that we value and excel at both patient care and basic science and clinical science. We are able to put our full weight on all the pathways to help children with cancer and blood disorders.

     

  • Education and Training

    Medical School

    Eastern Virginia Medical School, Norfolk, Va.

    Residency

    Resident in Pediatrics, Children's National Medical Center, Washington, DC

    Fellowship

    Clinical Fellow in Pediatric Hematology and Oncology, Children's Hospital of Philadelphia, Philadelphia, Pa. (2002-05)

    Board Certification

    American Board of Pediatrics/Hematology-Oncology
    American Board of Pediatrics

    Undergraduate Degree

    Postdoctoral Research Fellow in Pediatric Hematology and Oncology, Children's Hospital of Philadelphia, Philadelphia, Pa. (2003-05)

  • Titles and Academic Titles

    Attending physician

    Assistant professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Centers and Programs
  • Research Interests

    Novel therapeutics for leukemia and the Autoimmune Lymphoproliferative Syndrome

  • Publications

    Books

    Chapters

    Teachey DT, Rheingold S, Bunin N. Germ cell tumors. In: Brodeur G, Manno C, editors. Requisites in pediatrics: hematology and oncology. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.

    Teachey DT, Bunin N. Hematopoietic stem cell transplantation. In: Haelfer M, Chambers J, editors. Requisites in pediatrics: critical care medicine. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.

    Teachey DT. Lymphoproliferative disorders, myelodysplastic syndromes, and myeloproliferative disorders. In: Lanzkowsky P, editor. Manual of pediatric hematology/oncology. 5th ed. St. Louis:Academic Press, Elsevier; 2010.

    Teachey DT, Manno C. Hematologic manifestations of systemic disease. In: Brodeur G, Manno C, editors. Requisites in pediatrics: hematology and oncology. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.

    Teachey DT. Pallor. In: Schwartz MW, Bell LM, editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008.

    Teachey DT. Wilms Tumor. In: Schwartz WM, Bell LM Jr., editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008.

    Teachey DT. Acute myelogenous leukemia. In: Schwartz WM, Bell LM Jr., editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008. 

    Abstracts

    Brown VI, Sheen C, Ryan T, Hulitt, DiNardo L, Barrett D, Teachey DT, Grupp SA: The PIM-1 inhibitor SIG-1776 alone and in combination with the mTOR inhibitor rapamycin in efficacious in preclinical models of pre-B ALL. Blood 112: 1922, Nov 2008 Notes: ASH Annual Meeting

    Teachey DT, Sheen C, Brown VI, Grupp SA: Targeting eIF4E with ribavirin demonstrates a potentially effective strategy against acute lymphoblastic leukemia (ALL). Pediatr Blood and Cancer on line (www.aspho.org): 1296, May 2008 Notes: American Society of Pediatric Hematology/Oncology Annual Meeting.

    Teachey DT, Schwabe D, Bleesing J, Manno CS, Sullivan KS, Grupp SA: Sirolimus is a safe and effective treatment for patients with Autoimmune Lymphoproliferative Syndrome (ALPS). Pediatr Blood and Cancer on line (www.aspho.org): 1286, May 2008 Notes: American Society of Pediatric Hematology/Oncology Annual Meeting.

    Seif AE, Manno CS, Grupp SA, Teachey DT: Testing patients with Evans syndrome for the Autoimmune Lymphoproliferative Syndrome (ALPS): Results of a large multi-institutional clinical trial. Pediatr Blood and Cancer on line (www.aspho.org): 1299, May 2008 Notes: American Society of Pediatric Hematology/Oncology Annual Meeting *Plenary platform presentation.

    Rheingold SR, Sacks N, Chang YJ, Brown VI, Teachey DT, Lange BJ, Grupp SA: A phase I trial of sirolimus (rapamycin) in pediatric patients with relapsed/refractory leukemia. Blood 110: 2834, Nov 2007 Notes: ASH Annual Meeting

    Teachey DT, Seif A, Hall J, Ryan T, Sheen C, Reid G, Chang Y, Brown V, Grupp SA: Notch inhibitors are a safe and effective treatment for autoimmune lymphoproliferative syndrome. Pediatr Blood and Cancer 48: 6317.1, May 2007 Notes: American Society of Pediatric Hematology Oncology Annual Meeting, Oral Platform Presentation.

    Teachey DT, Reid G, Fish J, Sheen C, Ryan T, Hall J, Brown V, Grupp SA: mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Pediatr Blood and Cancer 48: 5725.4, May 2007 Notes: American Society of Pediatric Hematology Oncology Annual Meeting, Oral Platform Presentation.

    Teachey DT, Brown V, Reid G, Fish J, Grupp SA: mTOR inhibitors are synergistic with methotrexate: an effective combination to both prevent post-HSCT relapse of ALL and prevent GVHD. Biol Blood Marrow Transplant 13: 58, Feb 2007 Notes: ASBMT Tandem Transplant Meeting, February 2007, Oral Platform Presentation

     

     

    Papers

    2011

    Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. Epub 2011 Aug 16. doi: 10.1038/leu.2011.199. Cited in PubMed: PMID 21844871. Read the abstract

    Rothman JA, Das R, Teachey DT, Paessler ME, Nichols KE. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. Pediatr Blood Cancer. Epub 2011 Jun 16. doi: 10.1002/pbc.23226. Cited in PubMed: PMID 21681935. Read the abstract

    Sheen C, Vincent T, Barrett D, Horwitz EM, Hulitt J, Strong E. Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis. Br J Haematol. Epub 2011 May 9. doi: 10.1111/j.1365-2141.2011.08696.x. Cited in PubMed:PMID 21554258. No abstract available.

    Teachey DT. Autoimmune lymphoproliferative syndrome: new approaches to diagnosis and management. Clin Adv Hematol Oncol. 2011 mar;9(3):233-5. Cited in PubMed: PMID 21475130. No abstract available.

    2010 

    Kinjyo I, Gordon SM, Intlekofer AM, Dowdell K, Mooney EC, Caricchio R, et al. Cutting edge: lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin. J Immumol. 2010 Dec 15;185(12):7151-5. Epub 2010 Nov 12. Cited in PubMed: PMID 21076068. Read the abstract

    Teachey DT. Somatic ALPS: a FAScinating condition. Blood. 2010 Jun 24;115(25):5125-6. Cited in PubMed: PMID 20576815. No abstract available.

    Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010 Oct 7;116(14):e35-40. Epub 2010 Jun 10. Cited in PubMed: PMID 20538792. Read the abstract

    Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010 mar 18:115(11):2142-5. Epub 2010 Jan 12. Cited in PubMed: PMID 20068224. Read the article

    Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Hematol. 2010 Jan;148(2): 205-16, 2010. Epub 2009 Nov 23. Cited in PubMed: PMID 19930184. Read the article

    Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome (ALPS) in children with Evans syndrome: a multi-institutional study. Blood 2010 Mar;115(11): 2142-5. Epub 2010 Jan 12. Cited in PubMed: PMID 20068224. Read the article

    2009

    Teachey DT, Jubelirer T, Baluarte H, Wade A, Manno CS. Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant. Pediatr. Blood Cancer 53(6): 1114-6. Cited in PubMed: PMID 19621445. Read the abstract

    Teachey DT, Grupp SA, Brown VI. mTOR Inhibitors and their potential role for therapy in leukemia and other haematologic malignancies. Br. J. Haematol. 2009 Jun;145(5): 569-80. Epub 2009 Mar 16. Cited in PubMed: PMID 19344392. Read the article

    Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, et al.  Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 12009 Apr;45(1): 101-6. Epub 2009 Feb 4. Read the article

    Milone M, Fish JD, Carpenito C, Carroll R, Binder G, Teachey D, et al. Chimeric receptors containing CD137signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo. Mol Ther. 2009 Aug;17(8): 1453-64. Epub 2009 Apr 21. Cited in PubMed: PMID 19384291. Read the article